Racial differences in hepatitis C treatment eligibility

Hepatology

Volumn 54, Issue 1, 2011, Pages 70-78

  Melia, Michael T ^a   Muir, Andrew J ^b   Mccone, Jonathan ^c   Shiffman, Mitchell L ^d   King, John W ^e   Herrine, Steven K ^f   Galler, Greg W ^g   Bloomer, Joseph R ^h   Nunes, Frederick A ⁱ   Brown, Kimberly A ^j   Mullen, Kevin D ^k   Ravendhran, Natarajan ^l   Ghalib, Reem H ^m   Boparai, Navdeep ⁿ   Jiang, Ruiyun ⁿ   Noviello, Stephanie ⁿ   Brass, Clifford A ⁿ   Albrecht, Janice K ⁿ   Mchutchison, John G ^b   Sulkowski, Mark S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

^d Bon Secours Health System   (United States)

^e LOUISIANA STATE UNIVERSITY   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g Kelsey Seybold Research Foundation   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ PENNSYLVANIA HOSPITAL   (United States)

^j HENRY FORD HOSPITAL   (United States)

^k METROHEALTH MEDICAL CENTER   (United States)

^l Digestive Disease Associates   (United States)

^m Liver Instirtue at Methodist Dallas   (United States)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CREATININE; GLUCOSE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ALCOHOLISM; ANEMIA; ARTICLE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; GENOTYPE; HEART DISEASE; HEPATITIS C; HISPANIC; HUMAN; HYPERGLYCEMIA; MENTAL DISEASE; MULTICENTER STUDY (TOPIC); NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK FACTOR; SELF REPORT; TREATMENT CONTRAINDICATION; UNITED STATES;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALCOHOLISM; ANTIVIRAL AGENTS; DIABETES COMPLICATIONS; ELIGIBILITY DETERMINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART DISEASES; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MASS SCREENING; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RIBAVIRIN; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 79959567211     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24358     Document Type: Article

References (41)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 16; 144: 705-714.
2. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. HEPATOLOGY 2002; 36( 5 Suppl 1): S3-20.
3. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000; 119: 1317-1323.
4. Nguyen GC, Segev DL, Thuluvath PJ. Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. HEPATOLOGY 2007; 45: 1282-1289.
5. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-389.
6. Rousseau CM, Ioannou GN, Todd-Stenberg JA, Sloan KL, Larson MF, Forsberg CW, et al. Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. Am J Public Health 2008; 98: 846-852.
7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
8. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-2271.
9. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. HEPATOLOGY 2004; 39: 1702-1708.
10. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-477.
11. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 1335-1374.
12. Artinyan A, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, Bhatia S, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 2010; 116: 1367-1377.
13. Reed WW, Diehl LF. Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. Arch Intern Med 1991; 151: 501-505.
14. Streiff MB, Mehta S, Thomas DL. Peripheral blood count abnormalities among patients with hepatitis C in the United States. HEPATOLOGY 2002; 35: 947-952.
15. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
16. PEGASYS (peginterferon alfa-2a) Prescribing Information; Revised March 2010. Hoffman-La Roche, Nutley NJ. 2010.
17. PEGINTRON (peginterferon alfa-2b) Prescribing Information; Revised January 2010. Schering, Kenilworth, NJ. 2010.
18. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288-292.
19. Rowan PJ, Tabasi S, Abdul-Latif M, Kunik ME, El-Serag HB. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 2004; 38: 530-534.
20. Seal KH, Currie SL, Shen H, Anand BS, Bini EJ, Brau N, et al. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter? J Clin Gastroenterol 2007; 41: 199-205.
21. Markowitz JS, Gutterman EM, Hodes D, Klaskala W. Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. J Viral Hepat 2005; 12: 176-185.
22. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-264.
23. Mitchell AE, Colvin HM, Palmer BR. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. HEPATOLOGY 2010; 51: 729-733.
24. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000; 119: 1385-1396.
25. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291: 2720-2726.
26. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
27. Mederacke I, Wedemeyer H, Manns MP. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Investig Drugs 2009; 10: 181-189.
28. Twombly JG, Long Q, Zhu M, Wilson PW, Venkat NK, Fraser LA, et al. Diabetes care in black and white veterans in the southeastern United States. Diabetes Care 2010; 33: 958-963.
29. Adams AS, Zhang F, Mah C, Grant RW, Kleinman K, Meigs JB, et al. Race differences in long-term diabetes management in an HMO. Diabetes Care 2005; 28: 2844-2849.
30. Rhee MK, Cook CB, El-Kebbi I, Lyles RH, Dunbar VG, Panayioto RM, et al. Barriers to diabetes education in urban patients: perceptions, patterns, and associated factors. Diabetes Educ 2005; 31: 410-417.
31. Wilper AP, Woolhandler S, Lasser KE, McCormick D, Bor DH, Himmelstein DU. A national study of chronic disease prevalence and access to care in uninsured U.S. adults. Ann Intern Med 2008; 149: 170-176.
32. Hadley J, Steinberg EP, Feder J. Comparison of uninsured and privately insured hospital patients. Condition on admission, resource use, and outcome. JAMA 1991; 265: 374-379.
33. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis 2009; 53( 1 Suppl): S1-S374.
34. McClellan W, Warnock DG, McClure L, Campbell RC, Newsome BB, Howard V, et al. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol 2006; 17: 1710-1715.
35. Castro AF, Coresh J. CKD surveillance using laboratory data from the population-based National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009; 53( 3 Suppl 3): S46-S55.
36. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 243-250.
37. Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701-708.
38. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 2004; 43: 140-146.
39. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. HEPATOLOGY 2002; 36: 1273-1279.
40. Cooper CL, Al Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006; 42: 1674-1678.
41. Beutler E, West C. Hematologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. Blood 2005; 106: 740-745.